RA
BIIB icon

Resolute Advisors’s Biogen BIIB Stock Holding History

Resolute Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-145
Closed -$41K – 224
2021
Q3 		$41K Hold
145
– – 0.01% 135
2021
Q2 		$29K Buy
145
+89
+159% +$27K ﹤0.01% 135
2021
Q1 		$16K Buy
56
+51
+1,020% +$13.8K ﹤0.01% 175
2020
Q4 		$1K Buy
+5
New +$1.29K ﹤0.01% 96

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Resolute Advisors's BIIB Position: Q4 2021 in Review

Resolute Advisors sold out of Biogen (BIIB) in Q4 2021, closing a stake of 145 shares — an estimated $41K sold.

Resolute Advisors first reported a position in BIIB in Q4 2020 and held it in 4 quarters. The position peaked at $41K in Q3 2021. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

  • Resolute Advisors reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
  • Resolute Advisors sold 145 Biogen shares in Q4 2021, an estimated $41K.
  • Resolute Advisors first reported a position in Biogen in Q4 2020 and held it in 4 quarters.
  • Resolute Advisors's Biogen position peaked at $41K in Q3 2021.
  • 1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on Resolute Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.